Psoriatic arthritis: prospects for the future
Psoriatic arthritis (PsA) is a form of chronic inflammatory arthritis associated with psoriasis and a multitude of other symptoms, most commonly arthritis, dactylitis, enthesitis and axial involvement. PsA is significantly heterogeneous, with a highly variable clinical course of PsA. Patients may ex...
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
SAGE Publications
2022
|
| _version_ | 1826307644686598144 |
|---|---|
| author | Hackett, S Ogdie, A Coates, LC |
| author_facet | Hackett, S Ogdie, A Coates, LC |
| author_sort | Hackett, S |
| collection | OXFORD |
| description | Psoriatic arthritis (PsA) is a form of chronic inflammatory arthritis associated with psoriasis and a multitude of other symptoms, most commonly arthritis, dactylitis, enthesitis and axial involvement. PsA is significantly heterogeneous, with a highly variable clinical course of PsA. Patients may experience significant or mild skin and joint symptoms, with some patients developing rapidly progressing joint destruction and skin symptoms. Despite the range of symptom severity, PsA is frequently associated with significantly impaired quality of life from joint destruction, as well as chronic pain and a range of comorbidities such as depression and cardiovascular disease. Currently, there are no definitive diagnostic tests for PsA, with diagnosis remaining challenging owing to the heterogeneous presentation and course of the disease. Presently, the CASPAR criteria are often used to aid rheumatologists in distinguishing PsA from other inflammatory arthritides. Treatment options for patients have been expanded over the last two decades with the emerging clinical utility of biological therapies. However, early identification and diagnosis of patients and effective disease control remain unmet medical needs within the PsA community. In addition, predicting response to treatment also remains a challenge to rheumatologists. This review highlights the current hurdles faced by healthcare professionals in the diagnosis and management of PsA patients and provides future action points for consideration by the members of the multidisciplinary team who treat PsA patients. |
| first_indexed | 2024-03-07T07:07:47Z |
| format | Journal article |
| id | oxford-uuid:736fd9a0-d80d-4925-bc6f-a1ccb081e46b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:07:47Z |
| publishDate | 2022 |
| publisher | SAGE Publications |
| record_format | dspace |
| spelling | oxford-uuid:736fd9a0-d80d-4925-bc6f-a1ccb081e46b2022-05-17T14:22:33ZPsoriatic arthritis: prospects for the futureJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:736fd9a0-d80d-4925-bc6f-a1ccb081e46bEnglishSymplectic ElementsSAGE Publications2022Hackett, SOgdie, ACoates, LCPsoriatic arthritis (PsA) is a form of chronic inflammatory arthritis associated with psoriasis and a multitude of other symptoms, most commonly arthritis, dactylitis, enthesitis and axial involvement. PsA is significantly heterogeneous, with a highly variable clinical course of PsA. Patients may experience significant or mild skin and joint symptoms, with some patients developing rapidly progressing joint destruction and skin symptoms. Despite the range of symptom severity, PsA is frequently associated with significantly impaired quality of life from joint destruction, as well as chronic pain and a range of comorbidities such as depression and cardiovascular disease. Currently, there are no definitive diagnostic tests for PsA, with diagnosis remaining challenging owing to the heterogeneous presentation and course of the disease. Presently, the CASPAR criteria are often used to aid rheumatologists in distinguishing PsA from other inflammatory arthritides. Treatment options for patients have been expanded over the last two decades with the emerging clinical utility of biological therapies. However, early identification and diagnosis of patients and effective disease control remain unmet medical needs within the PsA community. In addition, predicting response to treatment also remains a challenge to rheumatologists. This review highlights the current hurdles faced by healthcare professionals in the diagnosis and management of PsA patients and provides future action points for consideration by the members of the multidisciplinary team who treat PsA patients. |
| spellingShingle | Hackett, S Ogdie, A Coates, LC Psoriatic arthritis: prospects for the future |
| title | Psoriatic arthritis: prospects for the future |
| title_full | Psoriatic arthritis: prospects for the future |
| title_fullStr | Psoriatic arthritis: prospects for the future |
| title_full_unstemmed | Psoriatic arthritis: prospects for the future |
| title_short | Psoriatic arthritis: prospects for the future |
| title_sort | psoriatic arthritis prospects for the future |
| work_keys_str_mv | AT hacketts psoriaticarthritisprospectsforthefuture AT ogdiea psoriaticarthritisprospectsforthefuture AT coateslc psoriaticarthritisprospectsforthefuture |